This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Governor Josh Shapiro and GSK leadership announced the global biopharma company’s major investment of up to $800 million in ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Also Read: GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement. Over half of all women are affected by uUTIs in their lifetime, with approximately 30% suffering from recurrent disease. New ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years Vandana Singh Wed, Oct 16, 2024, 11:35 AM 2 min read ...